01.26.16
ClinTec International has appointed Robert Reekie as chief operating officer and senior executive vice president. Dr. Reekie brings with him 30-years of drug development expertise and experience in commercializing a wide range of drug development services.
“As our company enters its 20th year of significant organic growth, Dr. Reekie represents a further strengthening and expansion of our senior executive leadership team,” said Rabinder Buttar, chief executive officer and founder of ClinTec International. “Dr. Reekie brings three decades of experience during which he has grown a CRO into a top 10 global player. Dr. Reekie will support our senior team in guiding ClinTec through further significant expansion during which we will retain a major focus on meeting the needs of our clients. He will steer the governance, operational delivery and further development of two major new preferred provider partnerships with leading pharmaceutical organizations. For one of these we are chosen as a full-service late phase clinical research partner for Europe and for the second one, a full-service global clinical program development partner”.
Dr. Reekie was previously chief operating officer for the Phase II-IV division at the large global CRO, inVentiv Health Clinical, and chief operating officer at its predecessor, PharmaNet Inc., ultimately responsible for operational delivery through an organization of 2500 staff based in over 40 countries.
“As our company enters its 20th year of significant organic growth, Dr. Reekie represents a further strengthening and expansion of our senior executive leadership team,” said Rabinder Buttar, chief executive officer and founder of ClinTec International. “Dr. Reekie brings three decades of experience during which he has grown a CRO into a top 10 global player. Dr. Reekie will support our senior team in guiding ClinTec through further significant expansion during which we will retain a major focus on meeting the needs of our clients. He will steer the governance, operational delivery and further development of two major new preferred provider partnerships with leading pharmaceutical organizations. For one of these we are chosen as a full-service late phase clinical research partner for Europe and for the second one, a full-service global clinical program development partner”.
Dr. Reekie was previously chief operating officer for the Phase II-IV division at the large global CRO, inVentiv Health Clinical, and chief operating officer at its predecessor, PharmaNet Inc., ultimately responsible for operational delivery through an organization of 2500 staff based in over 40 countries.